Filing Overview
Registrant: Eliem Therapeutics, Inc. (metadata identifies Climb Bio, Inc.; the filing itself names Eliem Therapeutics, Inc.). This Form 8-K was dated October 5, 2022, under Items 2.02, 7.01, 8.01 and 9.01. The disclosure furnished program updates, anticipated milestones, unaudited liquidity information and investor presentation materials.
Financial Position and Results
- Unaudited cash, cash equivalents and marketable securities were reported at approximately $129.8 million. The filing text refers to this balance as of September 30, 2022 in the introductory paragraph but as of September 20, 2022 in Item 2.02; the applicable date should be verified.
- The balance includes $6.2 million of tax reimbursements received during the third quarter of 2022.
- The filing does not provide revenue, net income or loss, operating cash flow, gross or operating margins, debt balances, burn rate or a detailed liquidity runway.
Material Developments and Outlook
ETX-155
- After lower-than-expected exposure in three subjects from a Phase 1b photosensitive epilepsy trial, Eliem conducted a Phase 1 pharmacokinetic study in healthy subjects.
- Single-dose results from 42 subjects indicated no meaningful batch-related exposure difference at 60 mg. The prior low exposures were characterized as within previously observed moderate variability. The company reported no identified chemistry, manufacturing or controls irregularities.
- The company plans to evaluate a 75 mg repeat dose before selecting the dose for a planned Phase 2a major depressive disorder trial.
- Final Phase 1 pharmacokinetic results, including the repeat-dose cohort, were expected in the fourth quarter of 2022. The Phase 2a trial was anticipated to begin in the first quarter of 2023, with topline data expected in mid-2024 if initiated as planned.
- Eliem decided not to restart the photosensitive epilepsy proof-of-concept trial, but plans to continue ETX-155 development for focal onset seizures.
Kv7.2/3 Program
- The preclinical program targets the Kv7.2/3 potassium channel for potential pain and epilepsy applications.
- Foundational intellectual property claims have been filed. Two pre-candidates were being scaled for IND-enabling safety studies expected in the first quarter of 2023, with Phase 1 studies planned for the first half of 2024.
- Additional preclinical data were expected later in the fourth quarter of 2022.
Discontinued Program
Early preclinical development of a novel, non-sedating generalized anxiety disorder candidate was discontinued because none of the evaluated compounds met the required profile.
Risks and Contingencies
Management’s milestones are forward-looking and depend on clinical safety and efficacy, pharmacokinetic results, trial initiation and enrollment, regulatory review, intellectual property protection, manufacturing, available capital, competition and operating conditions. The company specifically cautioned that ETX-155 or the Kv7 program may fail to demonstrate sufficient safety or efficacy, and that timing and expenses for development activities remain uncertain.
Investor Verification Points
- Confirm whether the reported $129.8 million liquidity balance is measured as of September 20 or September 30, 2022.
- Review the subsequent Phase 1 ETX-155 repeat-dose results and the selected dose for the Phase 2a MDD trial.
- Assess whether the Phase 2a MDD trial and Kv7 IND-enabling studies began on the stated timelines.
- Review subsequent filings for quarterly operating losses, cash burn, debt, financing activity and updated liquidity runway, none of which is quantified in this 8-K.
- Evaluate the implications of discontinuing the photosensitive epilepsy and generalized anxiety disorder programs for pipeline concentration and development risk.